Locations

Boca Raton4700 NW 2nd Ave, Suite 101
Boca Raton, FL 33431
Coral Springs5401 N University Drive, Suite 103
Coral Springs, FL 33067

Hours

  • Mon 08:30 AM – 5:30 PM
  • Tue 08:30 AM – 5:30 PM
  • Wed 08:30 AM – 5:30 PM
  • Thu 08:30 AM – 5:30 PM
  • Fri 08:30 AM – 5:30 PM
  • Sat Closed
  • Sun Closed

Follow Us

Is Spravato the Same as Ketamine? Differences Explained

spravato vs ketamine

No. Spravato is not the same as traditional ketamine, although the medications are closely related. Spravato contains esketamine, one molecular form of ketamine. Traditional racemic ketamine contains two molecular forms.

Spravato is an FDA-approved nasal spray for specific depression indications in adults. IV ketamine is used off-label for depression because its FDA approval covers anesthesia, not depression.

These differences affect treatment eligibility, administration, effectiveness research, safety monitoring, and insurance coverage. Understanding them helps patients compare their options without assuming one treatment is better for everyone.

Feature Spravato (Esketamine) IV Ketamine
Active medication S-ketamine (esketamine) Racemic mixture of R- and S-ketamine
Administration Nasal spray Intravenous infusion
FDA-approved for depression Yes, for specific adult indications No
Treatment setting REMS-certified healthcare setting Clinical setting with medical monitoring
Monitoring At least 2 hours after administration Depends on the treatment protocol
At-home administration Not permitted IV infusion requires clinical administration
Depression treatment schedule Defined in FDA prescribing information No FDA-approved depression schedule
Insurance coverage May be covered, depending on the plan Often limited for off-label depression treatment; verification required

Sources: FDA-approved Spravato prescribing information and FDA ketamine safety information.

What Is the Difference Between Spravato and Ketamine?

The main chemical difference is that Spravato contains esketamine, while traditional ketamine contains both esketamine and arketamine.

Both medications interact with the brain’s N-methyl-D-aspartate (NMDA) receptors, which are involved in glutamate signaling.

Glutamate is a neurotransmitter that helps nerve cells communicate. However, the precise mechanisms behind ketamine-related antidepressant effects remain under investigation.

What Does Spravato Contain?

Spravato contains esketamine hydrochloride, the S-enantiomer of ketamine.

An enantiomer is one of two molecular forms with the same chemical components but different three-dimensional arrangements.

Esketamine is also called S-ketamine.

Spravato delivers esketamine through a nasal spray designed for administration under healthcare professional supervision.

The FDA-approved formulation provides standardized dosing and specific instructions for clinical monitoring.

Esketamine interacts with NMDA receptors, but its precise antidepressant mechanism is not fully understood.

The presence of the S-form alone does not establish that Spravato works better or causes fewer side effects than racemic ketamine.

What Does Traditional Ketamine Contain?

Traditional ketamine contains two molecular forms:

  • R-ketamine (arketamine): One enantiomer of ketamine.
  • S-ketamine (esketamine): The other enantiomer, also present as the active medication in Spravato.

A medication containing both forms is called racemic ketamine.

Ketamine has an established medical use as an anesthetic. Healthcare professionals also administer it intravenously for depression in certain off-label treatment settings.

The difference in molecular composition does not make Spravato and IV ketamine interchangeable.

They have different formulations, dosing methods, regulatory indications, and treatment requirements.

Patients comparing the medications need to consider those clinical differences rather than chemical composition alone.

Are Spravato and Ketamine Both FDA-Approved for Depression?

No. Spravato is FDA-approved for specific adult depression indications, while traditional ketamine is FDA-approved for anesthesia but not depression.

This regulatory difference is important when evaluating treatment options, insurance coverage, and clinical monitoring requirements.

Which Depression Conditions Is Spravato Approved to Treat?

Spravato has two FDA-approved indications for adults.

1. Treatment-resistant depression (TRD)

Spravato is approved for adults with treatment-resistant depression, either:

  • As monotherapy, meaning without an accompanying oral antidepressant.
  • In conjunction with an oral antidepressant.

Treatment-resistant depression generally refers to depression that has not responded adequately to appropriate previous antidepressant treatments.

A psychiatrist reviews the patient’s medication history and clinical circumstances before determining whether the diagnosis and treatment indication apply.

2. Major depressive disorder with acute suicidal ideation or behavior

Spravato is also approved to treat depressive symptoms in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior.

For this indication, Spravato must be used alongside an oral antidepressant.

Important: FDA labeling states that Spravato has not demonstrated effectiveness in preventing suicide or reducing suicidal ideation or behavior.

Treatment with Spravato does not eliminate the need for hospitalization when clinically necessary.

Patients experiencing an immediate safety crisis require urgent assessment rather than waiting for an outpatient Spravato appointment.

The FDA expanded the adult treatment-resistant depression indication in January 2025 to permit Spravato monotherapy.

This means older articles stating that Spravato always requires an oral antidepressant are outdated.

Source: Janssen Pharmaceuticals, Spravato Prescribing Information, revised March 2026.

Why Is IV Ketamine Used Off-Label for Depression?

IV ketamine is used off-label for depression because its approved medical indications do not include psychiatric treatment.

The FDA has approved racemic ketamine injections for anesthesia.

However, clinical researchers have also studied ketamine’s antidepressant effects, particularly in patients whose depression has not improved adequately with established treatment.

Off-label use means a healthcare professional uses an approved medication for a condition or purpose outside its FDA-approved labeling.

Off-label prescribing is not automatically illegal or medically inappropriate. However, FDA approval for one condition does not establish effectiveness for another.

IV ketamine treatment for depression also lacks an FDA-approved depression dosing schedule.

Clinicians must assess the research evidence, potential benefits, risks, and available alternatives when considering off-label treatment.

Source: U.S. Food and Drug Administration, Compounding Risk Alerts, including its 2023 warning on ketamine products for psychiatric disorders.

How Is Spravato Treatment Different From IV Ketamine Infusions?

Spravato is administered as a supervised nasal spray, while IV ketamine is delivered through a vein.

The difference affects preparation, clinical monitoring, appointment duration, and transportation arrangements.

Neither treatment is equivalent to taking an ordinary antidepressant tablet at home.

What Happens During a Spravato Appointment?

A Spravato appointment takes place in a certified healthcare setting under professional supervision.

The patient administers the nasal spray while the healthcare professional observes.

A typical treatment process includes:

  1. Pre-treatment assessment: The provider reviews relevant symptoms, medications, and safety considerations.
  2. Blood-pressure check: The provider measures blood pressure before administration.
  3. Supervised administration: The patient uses the prescribed nasal spray under direct observation.
  4. Post-dose monitoring: The team monitors blood pressure, breathing, alertness, and other potential adverse effects.
  5. Discharge assessment: The provider confirms the patient is clinically stable before allowing departure.

The FDA requires observation for at least two hours after each Spravato treatment.

This is a minimum monitoring period. Patients who remain clinically unstable require further observation.

Patients must also arrange transportation home.

Driving, operating machinery, or performing activities requiring complete alertness is prohibited until the next day after restful sleep.

The prescribing information recommends avoiding food for at least two hours before treatment and liquids for at least 30 minutes beforehand.

Patients should follow the instructions provided by their treatment team.

For a more detailed appointment overview, read what Spravato treatment involves.

What Happens During an IV Ketamine Appointment?

IV ketamine treatment involves delivering the medication directly into a vein through an intravenous line.

The healthcare provider establishes the treatment plan and monitors the patient during administration.

A clinical appointment generally involves:

  1. Reviewing relevant medical information and treatment readiness.
  2. Placing an IV line for medication delivery.
  3. Administering ketamine according to the provider’s clinical protocol.
  4. Monitoring vital signs and treatment-related effects.
  5. Assessing recovery before discharge.

Treatment duration varies between providers because there is no FDA-approved IV ketamine regimen specifically for depression.

Patients should confirm the infusion duration, recovery requirements, and transportation restrictions with the clinic.

Sedation, impaired judgment, dizziness, and other treatment effects can make independent transportation unsafe.

IV ketamine treatment also requires appropriate medical supervision, even though it is not governed by the Spravato REMS program.

How Do Treatment Schedules Differ?

Spravato has an FDA-labeled schedule for adult treatment-resistant depression.

The schedule includes an initial induction phase followed by maintenance treatment when continued care is appropriate.

Treatment phase FDA-labeled Spravato frequency for adult TRD
Weeks 1–4 Twice weekly
Weeks 5–8 Once weekly
Week 9 onward Every two weeks or once weekly, based on response

The prescribing information directs clinicians to individualize treatment to the least frequent schedule needed to maintain response or remission.

The need for continued treatment is assessed after the four-week induction phase.

IV ketamine does not have an equivalent FDA-approved depression treatment schedule.

Research studies and clinical providers use different infusion schedules, treatment intervals, and follow-up approaches.

Patients should not assume that an IV ketamine protocol can be substituted directly for a Spravato schedule.

Source: Spravato FDA Prescribing Information, Section 2.2.

Does Spravato or IV Ketamine Work Better for Depression?

Current comparative evidence does not establish that Spravato or IV ketamine is consistently more effective for depression.

Both treatments have demonstrated antidepressant effects in clinical research. However, direct comparisons remain limited.

Differences in patient characteristics, dosing schedules, and research methods complicate treatment comparisons.

What Do Direct Comparison Studies Show?

A systematic review and meta-analysis published in November 2025 compared intravenous ketamine with esketamine for depression.

Elmosalamy and colleagues identified eight studies involving 978 patients.

Seven observational studies involving 915 patients compared IV ketamine with intranasal esketamine and were included in the pooled statistical analysis.

Researchers evaluated two main outcomes:

  • Treatment response: A clinically meaningful reduction in depressive symptoms.
  • Remission: Depression symptoms falling below a defined clinical threshold.

The pooled findings were:

Clinical outcome Statistical result Interpretation
Treatment response Odds ratio 1.26; p = 0.15 No statistically significant difference
Remission Odds ratio 1.31; p = 0.12 No statistically significant difference

Both results numerically favored IV ketamine, but neither difference reached conventional statistical significance.

The confidence intervals also included the possibility of no difference.

These findings do not establish that both treatments are equally effective.

Most included comparisons were observational rather than randomized controlled trials.

Observational studies can identify associations, but differences between patient groups can influence the findings.

The researchers concluded that larger randomized head-to-head trials are needed.

Source: Elmosalamy et al. (2025), Intravenous Ketamine Versus Esketamine for Depression: A Systematic Review and Meta-Analysis.

Does IV Ketamine Work Faster Than Spravato?

Some comparative studies suggest that IV ketamine may produce an earlier antidepressant response.

The 2025 review examined three studies that compared the time or number of treatment sessions required to achieve improvement.

One study reported a statistically significant difference favoring IV ketamine. Two others showed smaller, less conclusive trends.

However, the evidence was limited and largely observational.

Differences in treatment schedules, patient populations, and outcome measurements prevent a universal conclusion about speed.

Neither treatment guarantees relief after the first appointment.

A patient may experience early improvement, gradual improvement, or insufficient response.

The psychiatrist evaluates progress over the appropriate treatment period rather than predicting an exact response date.

Do We Know Which Treatment Has Longer-Lasting Results?

No. Current head-to-head research does not establish which treatment consistently produces longer-lasting remission.

The 2025 comparative review focused primarily on acute treatment outcomes.

Long-term results remain difficult to compare because follow-up periods and maintenance approaches vary between studies.

Spravato has clinical evidence supporting its labeled maintenance use in eligible patients.

IV ketamine has also been studied for repeated and longer-term treatment, but depression-specific maintenance protocols remain less standardized.

Research has not established that one approach consistently prevents relapse better than the other.

Patients should discuss how treatment response will be monitored and what follow-up care is available.

What the available comparison research establishes

Supported finding What remains uncertain
Both treatments have shown antidepressant effects Which is superior for every patient
The 2025 pooled comparison found no significant acute response difference Whether larger randomized trials will produce the same finding
Some studies suggest faster early response with IV ketamine Whether faster response occurs consistently
Both treatments require appropriate clinical monitoring Which has better long-term tolerability across comparable patients
Spravato has FDA-approved depression indications Which treatment produces longer remission in direct comparisons

What Are the Safety Differences Between Spravato and Ketamine?

Spravato and IV ketamine share certain safety concerns, but their monitoring requirements and approved treatment frameworks differ.

Both can affect alertness, perception, blood pressure, and other physiological functions.

The severity and frequency of adverse effects depend on the formulation, administered dose, patient characteristics, and clinical circumstances.

What Side Effects Can Occur With Either Treatment?

Commonly reported effects associated with ketamine-related treatment include:

  • Dissociation: Feeling disconnected from surroundings, thoughts, or the sense of self.
  • Sedation: Sleepiness or reduced alertness.
  • Dizziness: Lightheadedness or impaired balance.
  • Nausea: Stomach discomfort or an urge to vomit.
  • Blood-pressure changes: Temporary increases requiring medical monitoring.

These effects do not occur in every patient.

Research comparing adverse effects is influenced by differences in dosing and treatment protocols.

A specific study finding cannot establish that one treatment is always safer or better tolerated.

The FDA-approved Spravato label also includes warnings concerning respiratory depression, abuse, misuse, and impaired driving ability.

Patients seeking more detailed information can review Spravato side effects and safety risks.

Why Does Spravato Require REMS Monitoring?

Spravato is available through a restricted FDA safety program called the Risk Evaluation and Mitigation Strategy (REMS).

The program addresses serious risks associated with treatment.

These include:

  • Sedation.
  • Dissociation.
  • Respiratory depression.
  • Abuse and misuse.

Healthcare settings must be certified under the Spravato REMS program.

Patients receiving treatment in outpatient settings must be enrolled, and the medication is administered under direct professional observation.

Each treatment requires at least two hours of monitoring after dosing.

The FDA also requires monitoring of respiratory status, including pulse oximetry.

Pulse oximetry measures oxygen saturation in the blood.

A psychiatrist reviews medical factors that may affect treatment safety, including cardiovascular conditions, uncontrolled blood-pressure concerns, relevant neurological history, and substance-use risk.

Spravato is contraindicated in certain conditions, including aneurysmal vascular disease, arteriovenous malformation, previous intracerebral hemorrhage, and hypersensitivity to ketamine or esketamine.

REMS monitoring does not eliminate risk. It establishes specific safeguards around administration and observation.

Source: FDA-approved Spravato Prescribing Information, Section 5.

Is Compounded Ketamine Nasal Spray the Same as Spravato?

No. Compounded ketamine nasal spray is not the same as FDA-approved Spravato.

Spravato contains esketamine in a specific FDA-approved formulation.

Compounded ketamine nasal sprays contain ketamine prepared through pharmacy compounding. Their ingredients, concentrations, and instructions may differ from Spravato.

Compounded medications do not receive individual FDA approval before marketing.

This means the FDA has not evaluated each compounded product for safety, effectiveness, or quality through the standard drug-approval process.

In February 2022, the FDA issued a safety alert about compounded ketamine nasal spray.

The agency subsequently warned about additional risks associated with compounded ketamine products used for psychiatric disorders.

These concerns include:

  • Sedation and dissociation.
  • Blood-pressure changes.
  • Potential abuse and misuse.
  • Dosing and administration uncertainties.
  • Inadequate monitoring during unsupervised use.

Some compounded ketamine products are marketed for home administration.

However, at-home use without onsite medical monitoring introduces additional safety concerns.

Compounded does not automatically mean illegal or unsafe in every circumstance. Compounding can serve a legitimate medical need when an FDA-approved medication is not medically appropriate for a particular patient.

Nevertheless, compounded ketamine and Spravato have different regulatory requirements.

Patients should not assume that a compounded nasal ketamine product provides the same treatment, supervision, or evidence base as Spravato.

Source: U.S. Food and Drug Administration, Compounding Risk Alerts, February 2022 and October 2023.

How Do Spravato and IV Ketamine Differ in Cost and Insurance Coverage?

Spravato may qualify for insurance coverage under certain plans, while IV ketamine treatment for depression often faces limitations because the use is off-label.

Actual patient costs depend on the provider, insurer, treatment schedule, medical necessity, and individual benefits.

FDA approval does not guarantee reimbursement.

Does Insurance Cover Spravato for Depression?

Some insurance plans cover Spravato for eligible patients, but approval depends on the plan’s requirements.

Insurers may review:

  • The confirmed depression diagnosis.
  • Previous antidepressant treatment history.
  • Clinical documentation of inadequate response.
  • Medical-necessity criteria.
  • Prior authorization requirements.
  • Covered treatment locations and providers.

A patient may qualify medically for Spravato while still needing insurance authorization.

Deductibles, coinsurance, copayments, and other expenses can also vary.

Patients should request confirmation of both medication coverage and supervised administration costs.

Medicare billing guidance and medical coding information should not be interpreted as an automatic coverage guarantee.

Is IV Ketamine for Depression Usually Covered?

IV ketamine treatment for depression frequently faces insurance coverage limitations because the use is not FDA-approved for depression.

However, coverage cannot be described as universally unavailable.

Some plans or payment arrangements may differ, and individual circumstances require verification.

Patients should ask whether their insurer covers:

  • The ketamine medication.
  • The infusion procedure.
  • Clinical monitoring.
  • Related consultations.
  • Follow-up appointments.

Do not assume that coverage for ketamine anesthesia also applies to off-label depression infusions.

Request written confirmation before beginning treatment.

What Costs Should You Ask the Clinic About?

Comparing treatment costs requires reviewing the entire care process, not only the medication price.

Ask each provider for an itemized estimate covering:

  1. Initial evaluation: Psychiatric consultation and eligibility assessment.
  2. Medication: Spravato or ketamine administration costs.
  3. Treatment sessions: Professional services and clinical monitoring.
  4. Follow-up care: Progress assessments and additional appointments.
  5. Insurance responsibility: Prior authorization, deductibles, copayments, and coinsurance.
  6. Transportation: Travel arrangements when driving is restricted.
  7. Additional treatment: Potential costs if more sessions become clinically necessary.

For patients comparing Spravato and IV ketamine, the number of appointments can affect total expenses.

Spravato’s labeled treatment schedule also requires repeated travel to a certified healthcare setting.

An IV ketamine provider may use a different schedule, making direct price comparisons difficult without complete estimates.

How Can You Determine Which Treatment Option Is Appropriate for You?

To determine whether Spravato or IV ketamine deserves consideration, start with a psychiatric evaluation of your depression diagnosis, treatment history, and safety risks.

Neither treatment is appropriate for every patient.For treatment-resistant depression more broadly, see our guide comparing Spravato and TMS.

The decision requires more than comparing administration methods or reading personal treatment experiences.

What Should Your Psychiatrist Review Before Recommending Treatment?

A psychiatrist evaluates the patient’s medical and psychiatric history before recommending treatment.

Important factors include:

  • Depression diagnosis: Confirmation of major depressive disorder and relevant treatment indications.
  • Previous treatment response: Antidepressant medications, dosage, duration, and previous outcomes.
  • Current symptoms: Depression severity, functioning, and immediate safety concerns.
  • Medical history: Blood pressure, cardiovascular conditions, neurological history, and relevant contraindications.
  • Medication use: Current prescriptions and possible interactions.
  • Substance-use history: Factors relevant to abuse, misuse, and treatment safety.
  • Treatment goals: Expected benefits, limitations, and follow-up requirements.

For example, a patient with treatment-resistant depression and cardiovascular risk factors requires careful medical assessment before ketamine-related treatment.

A person experiencing an immediate psychiatric emergency may require a higher level of care rather than outpatient treatment.

The evaluation helps identify which options are clinically appropriate and which risks need further attention.

What Questions Should You Ask Before Choosing a Provider?

Patients comparing treatment providers should understand the actual service offered.

Use the following checklist before scheduling:

  • Is the medication FDA-approved for my depression indication?
  • Will I receive Spravato or racemic ketamine?
  • How is the medication administered?
  • Which safety assessments are completed beforehand?
  • How long will I remain under medical observation?
  • What side effects and complications does the team monitor?
  • How frequently are treatment appointments scheduled?
  • Will I need someone to drive me home?
  • How will treatment response be measured?
  • What happens if symptoms do not improve?
  • What insurance coverage or self-pay costs should I expect?

These questions are particularly important when comparing clinics that advertise different forms of ketamine treatment.

Lotus Psychiatry & Wellness provides Spravato treatment evaluations for eligible adults with depression.

The practice serves Boca Raton, Coral Springs, Parkland, and nearby South Florida communities.

A psychiatric evaluation can help determine whether Spravato is appropriate based on the patient’s previous treatment and current clinical needs.

Frequently Asked Questions About Spravato and Ketamine

Is Spravato a Type of Ketamine?

Yes. Spravato contains esketamine, the S-enantiomer of ketamine. Traditional racemic ketamine contains both S-ketamine and R-ketamine. Although chemically related, the medications have different formulations, administration methods, and FDA indications. Spravato is an approved nasal spray for specific adult depression indications, while IV racemic ketamine is used off-label for depression.

Is Esketamine Stronger Than Regular Ketamine?

Esketamine has different pharmacological properties from racemic ketamine, including differences in NMDA receptor binding. However, receptor activity alone does not establish greater clinical effectiveness. The 2025 head-to-head meta-analysis did not find a statistically significant difference in acute depression response or remission. Treatment effectiveness cannot be determined by describing one molecule as stronger.

Can You Use Spravato Without an Oral Antidepressant?

Yes. For adults with treatment-resistant depression, the FDA permits Spravato as monotherapy or alongside an oral antidepressant. However, its separate indication for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior requires an oral antidepressant. A psychiatrist determines the appropriate treatment plan based on the approved indication and patient assessment.

Is Spravato Available for At-Home Treatment?

No. Spravato must be administered under direct healthcare professional supervision in a REMS-certified healthcare setting. Patients require at least two hours of monitoring after each treatment. The medication is not dispensed for unsupervised home administration. Patients also need transportation home and must avoid driving until the following day after restful sleep.


Spravato and traditional ketamine are chemically related medications, but they differ in FDA approval, administration, treatment schedules, monitoring, and insurance considerations.

Current comparative research does not establish that either treatment is universally more effective for depression.

For patients whose depression has not improved adequately with established treatment, understanding these differences supports a more informed discussion with a psychiatrist.

Considering Spravato for Treatment-Resistant Depression?

Lotus Psychiatry & Wellness provides psychiatric evaluations and supervised Spravato treatment for eligible adults.

The practice serves patients in Boca Raton, Coral Springs, Parkland, and surrounding South Florida communities.

A psychiatric evaluation can help determine whether Spravato fits your diagnosis, treatment history, and medical needs.

Request a Spravato Treatment Evaluation

Call: (561) 563-6262